Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
jeudi, octobre 15
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
AVITA Medical Inc
RCEL
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$13.10
-0.26
-1.95%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Rapport sur les stocks
Privacy Manager
AVITA Medical Financials
AVITA Medical (RCEL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
This SpaceX Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Wall Street analysts upgraded AVITA, Etsy, Unity, and raised target prices for these stocks. See what others think before buying Unity.
Avi Kapoor
PRO
AVITA Medical Raises FY2026 Sales Guidance from $80.000M-$85.000M to $86.000M-$89.000M vs $82.350M Est
AVITA Medical (NASDAQ:RCEL) raises FY2026 sales outlook from $80.000 million-$85.000 million to $86.000 million-$89.000 million vs $82.350 million estimate.
Benzinga Newsdesk
PRO
AVITA Medical Q2 EPS $(0.25) Beats $(0.29) Estimate, Sales $21.702M Beat $20.167M Estimate
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.29) by 13.79 percent. This is a 34.21 percent increase over losses of $(0.38) per share from
Benzinga Newsdesk
PRO
AVITA Medical Affirms FY2026 Sales Guidance of $80.000M-$85.000M vs $82.258M Est
AVITA Medical (NASDAQ:RCEL) affirms FY2026 sales outlook from $80.000 million-$85.000 million to $80.000 million-$85.000 million vs $82.258 million estimate.
Benzinga Newsdesk
PRO
AVITA Medical Q1 EPS $(0.35) Misses $(0.28) Estimate, Sales $19.251M Beat $18.175M Estimate
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.28) by 25 percent. This is a 33.96 percent increase over losses of $(0.53) per share from the
Benzinga Newsdesk
Earnings Scheduled For May 14, 2026
Benzinga Insights
